Amgen Inc. (NASDAQ:AMGN) has a beta of 0.76, a 12-month trailing P/E ratio of 18.03, and a growth ratio of 2.71. The stock’s Relative Strength Index (RSI) is 43.69, with weekly volatility at 1.97% and ATR at 4.19. The AMGN stock’s 52-week price range has touched low of $177.05 and a $264.97 high. Its shares traded higher over the last trading session, gaining 0.32% on 12/29/20. The shares fell to a low of $223.03 before closing at $223.65. Intraday shares traded counted 1.49 million, which was 42.66% higher than its 30-day average trading volume of 2.60M. AMGN’s previous close was $222.93 while the outstanding shares total 585.00M.
Investors have identified the Drug Manufacturers – General company Amgen Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $130.21 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Amgen Inc. (AMGN) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For AMGN, the company has in raw cash 9.09 billion on their books with 91.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 22.66 billion total, with 9.95 billion as their total liabilities.
AMGN were able to record 7.91 billion as free cash flow during the Q3 2020 quarter of the year, this saw their quarterly net cash flow reduce by 3.05 billion. In cash movements, the company had a total of 8.34 billion as operating cash flow.
Potential earnings growth for Amgen Inc. (AMGN)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the Q3 2020 quarter of the year, Amgen Inc. recorded a total of 6.42 billion in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 10.68% coming in sequential stages and their sales for the Q3 2020 quarter increasing by 3.38%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 1.56 billion trying to sell their products during the last quarter, with the result yielding a gross income of 4.86 billion. This allows shareholders to hold on to 585.00M with the recently reported earning now reading 3.45 cents per share. This is a figure that compared to analyst’s prediction for their Q3 2020 (4.37 cents a share).
Having a look at the company’s valuation, the company is expected to record 17.01 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on AMGN sounds very interesting.
Is the stock of AMGN attractive?
In related news, Director, Williams R Sanders sold 250 shares of the company’s stock in a transaction that recorded on Nov 09. The sale was performed at an average price of 242.40, for a total value of 60,600. As the sale deal closes, the Director, SUGAR RONALD D now sold 1,000 shares of the company’s stock, valued at 241,020. Also, Director, Williams R Sanders sold 250 shares of the company’s stock in a deal that was recorded on Aug 07. The shares were price at an average price of 242.95 per share, with a total market value of 60,738. Following this completion of acquisition, the Director, SUGAR RONALD D now holds 1,000 shares of the company’s stock, valued at 259,790. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.19%.
14 out of 30 analysts covering the stock have rated it a Buy, while 15 have maintained a Hold recommendation on Amgen Inc.. 0 analysts has assigned a Sell rating on the AMGN stock. The 12-month mean consensus price target for the company’s shares has been set at $253.63.